Targeting EGFR, T790M, ALK, and ROS1 in NSCLC
By clicking the continue button above, I certify I have read the CME/CE information below.
Release Date: February 13, 2018
Expiration Date: February 13, 2019
Oncology treatment teams are tasked with navigating through a steady increase in the number and complexity of molecular biomarkers that guide treatment decisions. FDA-approved companion tests have expanded testing options and provide uniformity of reporting, yet challenges in the clinical setting and the potential to negatively impact patient outcomes persist. As part of the continuum of care in oncology, there is an increasing demand for genomic testing to guide the course of treatment.
Misinterpretation and over-interpretation of biomarker and genomic tests can be confusing. There is no shortage of targeted agents for the well-established molecular subtypes of non-small cell lung cancer (NSCLC); however, selecting the right agents for the right patients remains a challenge in the community setting. Appropriate evidence-based and quality care will directly affect reimbursement and incentives within the new payment models.
The primary audiences for this activity are:
- Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
- Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
- Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
- Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)
Benjamin Levy, MD
Clinical Director of The Sidney Kimmel Cancer Center
Johns Hopkins Medicine at Sibley Hospital
Benjamin Levy, MD is Assistant Professor at the Johns Hopkins School of Medicine and was recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine, at Sibley Hospital in Washington DC. Prior to his Hopkins appointment, Dr. Levy was Medical Director of Thoracic Oncology Program for Mount Sinai Health Systems and Associate Director of the Cancer Clinical Trials Office (CCTO). Dr. Levy is a physician scientist who is currently leading global immunotherapy trials evaluating checkpoint point inhibitors with novel combination strategies.
Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as Associate Editor for the ASCO University Committee, a committee whose mission is to develop and distribute web-based educational content to oncologists around the country. He recently completed 2 terms on the editorial board for the Journal of Clinical Oncology and currently serves as an ad hoc reviewer for other journals. He was recently selected as one of only 15 oncologists in the country to take part in the prestigious ASCO Leadership Development Program, whose mission is to identify and develop future leaders of ASCO. It addition to his ASCO commitments, Dr. Levy serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee, and IASLC Career Development & Fellowship Committee.
At the conclusion of this session, participants should be able to demonstrate the ability to:
- Incorporate treatment pathways and quality measures to ensure patients with lung cancer receive guideline-consistent care
- Evaluate the sequential and combination administration of targeted agents to optimize survival for patients with lung cancer
- Discuss current recommendations for diagnostic testing for lung cancer to facilitate treatment selection
- Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of lung cancer with attention to cost/benefit and toxicity considerations
- Employ resources to increase patient access and engagement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.
Total number of CE credits made available at this conference is 1.0 hours (0.10 CEUs).
A statement of credit will be issued only upon receipt of a completed activity evaluation.
This is an application-based activity.
For questions regarding CME/CE credit, the post-test, evaluation, please email email@example.com.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.1 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Benjamin Levy, MD: Consultant/Independent Contractor: AstraZeneca, Celgene, Takeda, Eli Lilly, Genentech, Pfizer, Bristol-Myers Squibb, Merck
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose
Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene
Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.